Webinar recording “Efficient Patient Identification in ALS Clinical Trials” now available

Two weeks ago, we presented the free webinar: "Efficient Patient Identification in…

Words Lucie van Leeuwen.Published November 24, 2020
Webinar recording “Efficient Patient Identification in ALS Clinical Trials” now available

Two weeks ago, we presented the free webinar: “Efficient Patient Identification in ALS Clinical Trials; Leveraging the Concept of Fast and Slow Progressors.” This was done in collaboration with Julius Clinical. Over 70 people registered to attend the webinar and we would like to thank everyone for their interest. We also have good news for anyone who missed the webinar or would like to watch it again. The video recording is now available for your viewing, and can be accessed below.

During this webinar, Prof. Dr. Leonard Van Den Berg and Dr. Ruben van Eijk (UMC Utrecht, the Netherlands) provided their insights on:

> Prediction-based inclusion criteria
> Defining the concept of fast vs slow progressors
> Addressing disease heterogeneity and reduce variance
> Regulatory perspective (EMA) on prediction-based patient selection

If you would like to learn more about the prediction model discussed in our webinar, discuss your trial design with the TRICALS team or if you have any other questions, please contact us at info@tricals.org.

Click on the button below to watch the webinar (starts at 06:56)

Watch Webinar

 


Share

Related news

Amylyx terminates open-label extension of the PHOENIX study
Amylyx terminates open-label extension of the PHOENIX study
The pharmaceutical company Amylyx has announced that they will terminate the open-label […]
Meet the centre - Torino ALS Center (University of Torino)
Meet the centre - Torino ALS Center (University of Torino)
The TRICALS consortium currently consists of more than 40 centers across Europe. […]
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug […]
Results of TUDCA-study: No effect of investigated compound
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study, […]